Vijaya Iyer is a freelance science writer for BioNews Services. She has contributed content to their several disease-specific websites, including cystic fibrosis, multiple sclerosis, muscular dystrophy, among others.
She holds a PhD in Microbiology from Kansas State University, where her research focused on molecular biology, bacterial interactions, metabolism, and animal models to study bacterial infections. Following the completion of her PhD, Dr. Iyer went on to complete three postdoctoral fellowships at Kansas State University, University of Miami and Temple University.
She joined BioNews Services to utilize her scientific background and writing skills to help patients and caregivers remain abreast with important scientific breakthroughs.
Disrupted blood cell production and markedly high rates of inflammation are seen in patients with juvenile idiopathic arthritis (JIA), Chinese researchers report. The study, “Characteristics of bone marrow cells in ... Read more
Imraldi, an adalimumab biosimilar of reference product Humira from AbbVie, will now be available to patients in the European Union, Samsung Bioepis the therapy’s maker, recently announced. In August 2017, the European Commission approved the ... Read more
Mylan and Fujifilm Kyowa Kirin Biologics were granted marketing authorization for biosimilar Hulio (adalimumab) by the European Commission for all the indications of its reference product, AbbVie‘s Humira (adalimumab), including juvenile ... Read more
In a nationwide public service announcement, former Pittsburgh Steelers quarterback Terry Bradshaw urges fellow rheumatic disease patients to take the pledge to manage their disease and live well. The announcement ... Read more
Kineret (anakinra), developed by Sobi, is now available as a treatment option in the United Kingdom for patients with systemic-onset juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD). This ... Read more
The phase 4 study evaluating H.P. Acthar Gel in patients with rheumatoid arthritis exceeded its enrollment goal, Mallinckrodt Pharmaceuticals announced. The ongoing study enrolled more than 230 adult patients over ... Read more
Treating children with juvenile idiopathic arthritis (JIA) helps them to achieve a quality of life comparable to that of any healthy child, and that is a realistic clinical goal, a German study ... Read more
Data from a national survey showed that adults with juvenile arthritis were obese and at significantly higher risk of developing metabolic syndrome, according to a new study. The survey was conducted ... Read more
In adolescents with juvenile idiopathic arthritis (JIA), high levels of depression at the time of their diagnosis may predict future pain and disability, according to researchers in the U.K. Their ... Read more